why choose us

Clinical Trials Search

Showing 8,540 of 132,366 result(s)
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Status: ACTIVE_NOT_RECRUITING

Condition: Solid Tumor, Adult

Interventions: Intra-tumoral administration on Days 1 and 15 of every 28-day cycle

Date: 2023-08-30

A Sequential Single and Multiple Ascending Dose (SAD;MAD) Study of SK10 Powders in Healthy Adult Subjects

Status: Completed

Condition: Chemotherapy-induced Diarrhea

Interventions: Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Date: 2023-08-30

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Status: NOT_YET_RECRUITING

Condition: Fibrolamellar Hepatocellular Carcinoma

Interventions: Patients will receive treatment on Day 1 of each cycle.
Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.

Date: 2023-08-30

Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

Status: NOT_YET_RECRUITING

Condition: Premature Birth

Interventions: The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechan

Date: 2023-08-30

Phase I Safety Study of B;HPIV3;S-6P Vaccine Via Nasal Spray in Adults

Status: Completed

Condition: SARS-CoV-2 Infection

Interventions: Intranasal vaccine.

Date: 2023-08-30

Priming Expectations and Motor Learning With tDCS

Status: Completed

Condition: Expectations

Interventions: Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electri

Date: 2023-08-30

Enfamil NeuroPro Study

Status: Completed

Condition: Infant Development

Interventions: FDA Infant formula

Date: 2023-08-30

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Patients With Generalized Anxiety Disorder (GAD) and Patients With Schizophrenia (SCZ)

Status: Completed

Condition: Healthy Volunteers Generalized Anxiety Disorder (GAD) Schizophrenia (SCZ)

Interventions: Capsule; oral

Date: 2023-08-30

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Status: Completed

Condition: Progressive Pulmonary Fibrosis

Interventions: Specified dose on specified days

Date: 2023-08-30

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms

Status: Completed

Condition: Myeloproliferative Neoplasms

Interventions: INCA033989 will be administered at protocol defined dose.

Date: 2023-08-30